==== Front Chin Med J (Engl)Chin. Med. JCMJChinese Medical Journal0366-6999Medknow Publications & Media Pvt Ltd India 30058571CMJ-131-176510.4103/0366-6999.237413EditorialCurrent Treatment for Central Nervous System Involvement in Children with Hemophagocytic Lymphohistiocytosis Zheng Hu-Yong Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education, Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, ChinaAddress for correspondence: Prof. Hu-Yong Zheng, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education, Hematology Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China E-Mail: zhenghuyong@vip.sina.com05 8 2018 131 15 1765 1766 06 6 2018 Copyright: © 2018 Chinese Medical Journal2018This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.Central Nervous SystemChildrenHemophagocytic LymphohistiocytosisInvolvement ==== Body Hemophagocytic lymphohistiocytosis (HLH) is a severe life-threatening clinical syndrome with hyperinflammation rather than an isolated disease. It is classified as primary HLH and secondary HLH. Primary HLH is associated with HLH-related gene mutations, whereas secondary HLH occurs after severe infections, tumors, connective tissue diseases, etc.[1] Regardless of primary or secondary HLH, 30–73% of patients have central nervous system (CNS) involvement.[2] Among adults with HLH in China, 38.4% of patients have neurological symptoms at the onset, and there are up to 89.6% with neurological symptoms during the entire course of the disease.[3] However, it has not been clearly reported about the CNS involvement in children with HLH. In this issue of CMJ, Zhao et al.[4] reported a retrospective single-institution study evaluating the involvement of CNS in 179 children with HLH. It was found that 21.2% of HLH children had neurological symptoms at the onset, 50% had cranial imaging changes, and 14.7% had cerebrospinal fluid (CSF) abnormal. In total, 60.3% of the children with HLH had CNS involvement including one of the presences such as CNS symptoms, imaging abnormalities, and changes in CSF. The results suggested that children with HLH suffering from CNS involvement had a poor prognosis. Therefore, clinical attention should be paid to the presence of HLH children with CNS involvement. Early diagnosis and timely treatment is particularly important to improve its outcome. Cranial magnetic resonance imaging (MRI) and CSF examinations are necessary for all HLH children diagnosed according to the HLH-2004 protocol.[5] Importantly, this study found that the clinical symptoms combined CSF abnormality had more prognostic significance than simple CNS imaging changes. How to treat patients with HLH complicated with CNS involvement? The HLH-94/04 protocol is the basic regimen, supplemented with intrathecal injection of methotrexate and glucocorticoid. In the case of primary HLH, hematopoietic stem cell transplantation (HSCT) is suggested to perform as soon as possible after induction of remission. For secondary HLH, induction of remission should be followed by treatment of the underlying diseases. If the HLH still could not be controlled, high-dose steroid pulse therapy, anti-CD52 monoclonal antibody (alemtuzumab), or new biological agents (such as anti-interferon-γ antibody or ruxolitinib) should be administered. Salvage therapy or HSCT could be considered for the HLH patients who failed to the above treatment.[678] In clinical practice, the treatment regimen will be adjusted according to patient's conditions. The appropriate treatment plan is crucial for the children with HLH, especially for whom have CNS involvement. In conclusion, HLH is a lethal syndrome triggered by an inflammatory cytokine storm. The presence of CNS involvement is a poor prognostic sign and should be carefully investigated for the neurological symptoms, brain MRI with multifocal white matter abnormalities and CSF examinations. Early diagnosis of CNS involvement will apparently increase timely and appropriate treatment to improve the prognosis of children with HLH. Edited by: Peng Lyu ==== Refs REFERENCES 1 Janka GE Lehmberg K Hemophagocytic syndromes – An update Blood Rev 2014 28 135 42 doi: 10.1016/j.blre.2014.03.002 24792320 2 Kim MM Yum MS Choi HW Ko TS Im HJ Seo JJ Central nervous system (CNS) involvement is a critical prognostic factor for hemophagocytic lymphohistiocytosis Korean J Hematol 2012 47 273 80 doi: 10.5045/kjh.2012.47.4.273 23320006 3 Song Y Pei RJ Wang YN Zhang J Wang Z Central nervous system involvement in hemophagocytic lymphohistiocytosis in adults: A retrospective analysis of 96 patients in a single center Chin Med J 2018 131 776 83 doi: 10.4103/0366-6999.228234 29578120 4 Zhao YZ Li ZG Zhang L Lian HY Ma HH Wang D Central nervous system involvement in 179 Chinese children with hemophagocytic lymphohistiocytosis Chin Med J 2018 131 1786 92 30058574 5 Henter JI Horne A Aricó M Egeler RM Filipovich AH Imashuku S HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis Pediatr Blood Cancer 2007 48 124 31 doi: 10.1002/pbc.21039 16937360 6 Horne A Wickström R Jordan MB Yeh EA Naqvi A Henter JI How to treat involvement of the central nervous system in hemophagocytic lymphohistiocytosis? Curr Treat Options Neurol 2017 19 3 doi: 10.1007/s11940-017-0439-4 28155064 7 Jordan MB Allen CE Weitzman S Filipovich AH McClain KL How I treat hemophagocytic lymphohistiocytosis Blood 2011 118 4041 52 doi: 10.1182/blood-2011-03-278127 21828139 8 Wang Y Wang Z Treatment of hemophagocytic lymphohistiocytosis Curr Opin Hematol 2017 24 54 8 doi: 10.1097/MOH.0000000000000302 27755125